Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J5TN
|
|||
| Former ID |
DNC000402
|
|||
| Drug Name |
CEP-751
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neurodegenerative disorder [ICD-11: 8A20-8A23] | Terminated | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H23N3O4
|
|||
| Canonical SMILES |
CC12C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)OC
|
|||
| InChI |
1S/C27H23N3O4/c1-26-27(13-31,33-2)11-19(34-26)29-17-9-5-3-7-14(17)21-22-16(12-28-25(22)32)20-15-8-4-6-10-18(15)30(26)24(20)23(21)29/h3-10,19,31H,11-13H2,1-2H3,(H,28,32)/t19?,26-,27-/m0/s1
|
|||
| InChIKey |
NMMGUHANGUWNBN-OGLOGDKOSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proto-oncogene c-Ret (RET) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Endocytosis | |||
| Pathways in cancer | ||||
| Thyroid cancer | ||||
| Central carbon metabolism in cancer | ||||
| Pathway Interaction Database | Signaling events regulated by Ret tyrosine kinase | |||
| Posttranslational regulation of adherens junction stability and dissassembly | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Dopaminergic Neurogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008742) | |||
| REF 2 | CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res. 2003 Sep 1;63(17):5559-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.